PL3448364T3 - Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyń - Google Patents
Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyńInfo
- Publication number
- PL3448364T3 PL3448364T3 PL17790646.8T PL17790646T PL3448364T3 PL 3448364 T3 PL3448364 T3 PL 3448364T3 PL 17790646 T PL17790646 T PL 17790646T PL 3448364 T3 PL3448364 T3 PL 3448364T3
- Authority
- PL
- Poland
- Prior art keywords
- atherosclerosis
- resolve
- targeting
- immune system
- innate immune
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 238000009825 accumulation Methods 0.000 title 1
- 210000005007 innate immune system Anatomy 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 210000002540 macrophage Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1224—Lipoprotein vesicles, e.g. HDL and LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329676P | 2016-04-29 | 2016-04-29 | |
| PCT/US2017/030444 WO2017190145A1 (en) | 2016-04-29 | 2017-05-01 | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3448364T3 true PL3448364T3 (pl) | 2022-08-16 |
Family
ID=60161161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17790646.8T PL3448364T3 (pl) | 2016-04-29 | 2017-05-01 | Celowanie we wrodzony układ immunologiczny dla wywołania długotrwałej tolerancji i wyeliminowania akumulacji makrofagów w miażdżycy naczyń |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190290593A1 (pl) |
| EP (2) | EP3448364B1 (pl) |
| JP (2) | JP7262100B2 (pl) |
| CN (2) | CN109640959B (pl) |
| AU (3) | AU2017257189B2 (pl) |
| CA (1) | CA3021645A1 (pl) |
| DK (1) | DK3448364T3 (pl) |
| ES (1) | ES2913073T3 (pl) |
| PL (1) | PL3448364T3 (pl) |
| PT (1) | PT3448364T (pl) |
| WO (1) | WO2017190145A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3448364T3 (da) * | 2016-04-29 | 2022-05-02 | Icahn School Med Mount Sinai | Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose |
| WO2019100044A1 (en) * | 2017-11-20 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| US20230001010A1 (en) * | 2019-07-19 | 2023-01-05 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
| EP4061408A4 (en) * | 2019-11-22 | 2024-04-10 | The Research Foundation for the State University of New York | Compositions and methods for use in type 1 diabetes |
| CN111494320A (zh) * | 2020-04-24 | 2020-08-07 | 上海交通大学医学院附属仁济医院 | 一种载糖皮质激素的纳米载体及其制备和应用 |
| CA3187283A1 (en) * | 2020-06-29 | 2022-01-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-protein s single-domain antibodies and polypeptides comprising thereof |
| KR20230171435A (ko) * | 2021-03-19 | 2023-12-20 | 트레인드 테라퓨틱스 디스커버리, 아이엔씨. | 훈련된 면역을 조절하기 위한 화합물 및 이의 사용 방법 |
| CN114788835B (zh) * | 2022-04-07 | 2024-01-23 | 中山大学附属第三医院 | Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1138436A (en) | 1978-02-24 | 1982-12-28 | Gerhard Baschang | Process for the manufacture of novel antigens |
| JPS5528933A (en) | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
| JPS5618996A (en) | 1979-06-21 | 1981-02-23 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide derivative |
| FI75578C (fi) | 1979-07-25 | 1988-07-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider. |
| JPS58172399A (ja) | 1982-04-05 | 1983-10-11 | Dai Ichi Seiyaku Co Ltd | ムラミルトリペプチド誘導体 |
| EP0102319B1 (de) | 1982-07-23 | 1987-08-19 | Ciba-Geigy Ag | Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen |
| GR851293B (pl) | 1984-05-29 | 1985-11-25 | Ciba Geigy Ag | |
| JPS6157597A (ja) | 1984-08-29 | 1986-03-24 | Toshiyuki Hamaoka | ムラミルペプチド活性エステル誘導体 |
| EP0192611A3 (de) | 1985-02-20 | 1988-05-11 | Ciba-Geigy Ag | Acylierte Hexosederivate und Verfahren zu ihrer Herstellung |
| EP0192609A3 (de) | 1985-02-20 | 1988-04-27 | Ciba-Geigy Ag | Acylierte Hexosederivate und Verfahren zu ihrer Herstellung |
| US4640911A (en) | 1985-05-29 | 1987-02-03 | Ciba-Geigy Corporation | Acylated sugar derivatives, processes for their manufacture, and their use |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| RU2139086C1 (ru) | 1991-11-19 | 1999-10-10 | Закрытое акционерное общество "ПЕПТЕК" | Способ лечения септического шока и применение мурамиловых соединений |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5349060A (en) | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9320820D0 (en) | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
| PL314238A1 (en) | 1993-12-17 | 1996-09-02 | Sandoz Ltd | Rapamycin derivatives |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| GB9413935D0 (en) | 1994-07-11 | 1994-08-31 | Peptech Uk Ltd | Use of maramyl peptide compounds |
| GB9419011D0 (en) | 1994-09-21 | 1994-11-09 | Peptech Uk Ltd | Use of muramyl peptide compounds |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| ATE228135T1 (de) | 1995-06-09 | 2002-12-15 | Novartis Erfind Verwalt Gmbh | Rapamycinderivate |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| GB9618673D0 (en) | 1996-09-06 | 1996-10-16 | Peptech Uk Ltd | The use of muramyl peptides |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| US7592008B2 (en) | 2000-11-20 | 2009-09-22 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Membrane scaffold proteins |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| CN100560719C (zh) | 2003-03-26 | 2009-11-18 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| CA2549341C (en) | 2003-12-19 | 2014-06-10 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
| SG152234A1 (en) | 2004-04-14 | 2009-05-29 | Wyeth Corp | Regiospecific synthesis of rapamycin 42-ester derivatives |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| EP1828219A4 (en) | 2004-11-17 | 2008-07-23 | Protiva Biotherapeutics Inc | ARNSI SILENCE OF APOLIPOPROTEIN B |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007022474A2 (en) | 2005-08-19 | 2007-02-22 | Cylene Pharmaceuticals, Inc. | HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF |
| CA2683063A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| CN101096386A (zh) | 2007-06-05 | 2008-01-02 | 复旦大学 | Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| CA2701630C (en) | 2007-10-05 | 2016-10-25 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
| CA2917512C (en) | 2007-10-12 | 2025-08-05 | President And Fellows Of Harvard College | VACCINE NANOTECHNOLOGY |
| EP2217221B1 (en) | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| EP2229411B1 (en) | 2007-12-12 | 2019-02-27 | University Health Network | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| EP2262489A2 (en) | 2008-02-28 | 2010-12-22 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| US8563603B2 (en) | 2008-10-22 | 2013-10-22 | Cornell University | Polycyclic compounds and methods related thereto |
| WO2010047839A1 (en) | 2008-10-25 | 2010-04-29 | Aura Biosciences | Modified plant virus particles and uses therefor |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US9408873B2 (en) | 2010-08-23 | 2016-08-09 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases |
| KR101253399B1 (ko) * | 2010-10-26 | 2013-04-11 | 영남대학교 산학협력단 | 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형 |
| US20140086839A1 (en) | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| CN102178954B (zh) | 2011-04-25 | 2014-05-28 | 中国药科大学 | 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US20150182461A1 (en) * | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
| EP2703384A1 (en) | 2012-08-27 | 2014-03-05 | Ludwig-Maximilians-Universität München | Inhibitors of CD40-TRAF6 interaction |
| CN103589699B (zh) | 2013-11-05 | 2015-05-13 | 江南大学 | 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶 |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| EP3074391B1 (en) | 2013-11-28 | 2019-07-31 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| US10610564B2 (en) | 2015-02-26 | 2020-04-07 | Stc.Unm | IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy |
| WO2016154544A1 (en) | 2015-03-25 | 2016-09-29 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2016154542A2 (en) | 2015-03-25 | 2016-09-29 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
| WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
| EP3285814B1 (en) | 2015-04-20 | 2020-06-24 | Memorial Sloan-Kettering Cancer Center | Imaging of tumor-associated macrophages |
| US10988508B2 (en) | 2015-04-24 | 2021-04-27 | University Of Delaware | Synthetic N-acetyl-muramic acid derivatives and uses thereof |
| CN106714836A (zh) | 2015-06-05 | 2017-05-24 | H·李·莫菲特癌症中心研究有限公司 | Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗 |
| WO2017011685A1 (en) | 2015-07-15 | 2017-01-19 | Celator Pharmaceuticals, Inc. | Improved nanoparticle delivery systems |
| WO2017024312A1 (en) | 2015-08-06 | 2017-02-09 | Autotelic Llc | Phospholipid-cholesteryl ester nanoformulations and related methods |
| JP6899154B2 (ja) * | 2015-12-18 | 2021-07-07 | ノースウェスタン ユニバーシティ | 一酸化窒素放出高密度リポタンパク質様ナノ粒子（ｎｏ ｈｄｌ ｎｐｓ） |
| US20190008918A1 (en) | 2016-03-08 | 2019-01-10 | Bioxcel Corporation | Immunomodulation therapies for cancer |
| DK3448364T3 (da) * | 2016-04-29 | 2022-05-02 | Icahn School Med Mount Sinai | Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose |
| WO2017205536A2 (en) | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| WO2018071549A1 (en) | 2016-10-11 | 2018-04-19 | New York University | Nanoparticles and uses thereof |
| CN106831614B (zh) | 2017-01-09 | 2020-07-28 | 清华大学 | 取代的苯并二氮杂环类化合物及其制备方法和用途 |
| CA3057715A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| WO2019100044A1 (en) | 2017-11-20 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| CN111971028A (zh) | 2017-11-21 | 2020-11-20 | 西奈山伊坎医学院 | 用治疗性纳米生物组合物促进训练免疫 |
| KR102198900B1 (ko) | 2019-05-10 | 2021-01-07 | 서강대학교 산학협력단 | 질병 치료용 나노입자 복합체 및 이의 제조방법 |
| KR20230171435A (ko) | 2021-03-19 | 2023-12-20 | 트레인드 테라퓨틱스 디스커버리, 아이엔씨. | 훈련된 면역을 조절하기 위한 화합물 및 이의 사용 방법 |
| WO2023192956A2 (en) | 2022-03-31 | 2023-10-05 | Icahn School Of Medicine At Mount Sinai | Sphingolipid-loaded nanobiologics for immune regulation |
-
2017
- 2017-05-01 DK DK17790646.8T patent/DK3448364T3/da active
- 2017-05-01 WO PCT/US2017/030444 patent/WO2017190145A1/en not_active Ceased
- 2017-05-01 ES ES17790646T patent/ES2913073T3/es active Active
- 2017-05-01 JP JP2018556339A patent/JP7262100B2/ja active Active
- 2017-05-01 CA CA3021645A patent/CA3021645A1/en active Pending
- 2017-05-01 CN CN201780041257.3A patent/CN109640959B/zh active Active
- 2017-05-01 EP EP17790646.8A patent/EP3448364B1/en active Active
- 2017-05-01 CN CN202310107087.1A patent/CN116077439A/zh active Pending
- 2017-05-01 PT PT177906468T patent/PT3448364T/pt unknown
- 2017-05-01 US US16/097,013 patent/US20190290593A1/en not_active Abandoned
- 2017-05-01 EP EP22155443.9A patent/EP4014967A1/en active Pending
- 2017-05-01 AU AU2017257189A patent/AU2017257189B2/en active Active
- 2017-05-01 PL PL17790646.8T patent/PL3448364T3/pl unknown
-
2022
- 2022-06-30 AU AU2022204675A patent/AU2022204675B2/en active Active
-
2023
- 2023-03-14 US US18/121,527 patent/US12377054B2/en active Active
- 2023-04-04 JP JP2023060872A patent/JP2023085437A/ja active Pending
-
2025
- 2025-08-14 AU AU2025217324A patent/AU2025217324A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021645A1 (en) | 2017-11-02 |
| US20230218537A1 (en) | 2023-07-13 |
| AU2022204675A1 (en) | 2022-09-15 |
| CN116077439A (zh) | 2023-05-09 |
| WO2017190145A1 (en) | 2017-11-02 |
| EP4014967A1 (en) | 2022-06-22 |
| AU2022204675B2 (en) | 2025-09-04 |
| ES2913073T3 (es) | 2022-05-31 |
| EP3448364A1 (en) | 2019-03-06 |
| EP3448364A4 (en) | 2019-12-25 |
| AU2025217324A1 (en) | 2025-09-04 |
| CN109640959B (zh) | 2023-03-17 |
| JP7262100B2 (ja) | 2023-04-21 |
| EP3448364B1 (en) | 2022-02-09 |
| CN109640959A (zh) | 2019-04-16 |
| US20190290593A1 (en) | 2019-09-26 |
| US12377054B2 (en) | 2025-08-05 |
| AU2017257189A1 (en) | 2018-11-15 |
| DK3448364T3 (da) | 2022-05-02 |
| JP2019515926A (ja) | 2019-06-13 |
| AU2017257189B2 (en) | 2022-03-31 |
| JP2023085437A (ja) | 2023-06-20 |
| PT3448364T (pt) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3448364T (pt) | Direcionamento do sistema imunitário inato para induzir uma tolerância a longo prazo e para resolver a acumulação de macrófagos na aterosclerose | |
| IL257571A (en) | A system for creating a spray with a condenser | |
| IL259244B (en) | A system for creating a spray with a motor | |
| GB2550066B8 (en) | Online collaboration systems and methods | |
| PL3033559T3 (pl) | Zespół typu kołnierzowego i nieprzepuszczające cieczy złącze z takim zespołem | |
| ZA201808059B (en) | Improvements in or relating to connecting devices | |
| HUE037874T2 (hu) | Mozgás- és/vagy pozíció-detektálással rendelkezõ tisztítórendszer | |
| IL247189B (en) | A system for comparing and merging versions in editing websites and interactive applications | |
| GB201507240D0 (en) | Improvements in or relating to heat transfer systems | |
| GB2528907B (en) | Improvements in or relating to furniture | |
| EP3174984A4 (en) | Antagonistic ctla-4 aptamers and applications thereof in enhancing immune activity | |
| PL3047159T3 (pl) | Łącznik do profili jak również zespolenie profili | |
| IL258667A (en) | Improvements in/and related to missile homing | |
| GB2563751B (en) | Improvements in and relating to heating and cooling systems | |
| ZA201701782B (en) | Rail member and rail system | |
| HK40093107A (zh) | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 | |
| PL3274637T3 (pl) | Kocioł i drzwi do tego kotła | |
| GB2563535B (en) | Improvements in and relating to video multiviewer systems | |
| GB2552573B (en) | Interactive greeting card with infrared sensor | |
| GB201515226D0 (en) | Improvements in or relating to heating and cooling systems | |
| GB2545227B (en) | Improvements in and relating to remote sensing | |
| GB2545341B (en) | Improvements in and relating to remote sensing | |
| GB201509183D0 (en) | Improvements in and relating to munitions systems | |
| GB201504981D0 (en) | Connector assembly and retaining bush | |
| GB201620626D0 (en) | Improvements in and relating to remote sensing |